CLINICAL TRIALS PROFILE FOR ESKALITH CR
✉ Email this page to a colleague
All Clinical Trials for Eskalith Cr
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00057681 ↗ | Study of Outcome and Safety of Lithium, Divalproex and Risperidone for Mania in Children and Adolescents | Completed | National Institute of Mental Health (NIMH) | Phase 3 | 2003-02-01 | This study will evaluate the effectiveness of the medications, lithium (Eskalith®), valproate (Depakote®), and risperidone (Risperdal®) in treating children and adolescents with bipolar disorder or symptoms of mania. |
NCT00057681 ↗ | Study of Outcome and Safety of Lithium, Divalproex and Risperidone for Mania in Children and Adolescents | Completed | Washington University School of Medicine | Phase 3 | 2003-02-01 | This study will evaluate the effectiveness of the medications, lithium (Eskalith®), valproate (Depakote®), and risperidone (Risperdal®) in treating children and adolescents with bipolar disorder or symptoms of mania. |
NCT00221975 ↗ | Combination Therapy in Dual Diagnosis Bipolar Rapid Cycling | Completed | University Hospitals Cleveland Medical Center | Phase 3 | 2002-07-01 | Combination Therapy in Dual Diagnosis Bipolar Rapid Cycling: This study recruits males and females age 18 and older who currently meet diagnostic criteria for rapid cycling bipolar disorder (type I or II) and who have met the criteria for substance abuse or dependence of cocaine, marijuana and/or alcohol within the past six months. Patients begin treatment with a combination of lithium and divalproex. Once these medications are tolerated, they are randomly assigned to double-blind treatment with lamotrigine or placebo. Patients remain in this study until they experience a marked bimodal response for four consecutive weeks. This study is sponsored by the Stanley Foundation. |
NCT00408681 ↗ | Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant | Completed | National Cancer Institute (NCI) | N/A | 2006-06-01 | RATIONALE: Lithium carbonate may be an effective treatment for intestinal graft-versus-host disease caused by a donor stem cell transplant. PURPOSE: This clinical trial is studying lithium carbonate in treating patients with acute intestinal graft-versus-host-disease after donor stem cell transplant. |
NCT00408681 ↗ | Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant | Completed | Fred Hutchinson Cancer Research Center | N/A | 2006-06-01 | RATIONALE: Lithium carbonate may be an effective treatment for intestinal graft-versus-host disease caused by a donor stem cell transplant. PURPOSE: This clinical trial is studying lithium carbonate in treating patients with acute intestinal graft-versus-host-disease after donor stem cell transplant. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Eskalith Cr
Condition Name
Clinical Trial Locations for Eskalith Cr
Trials by Country
Clinical Trial Progress for Eskalith Cr
Clinical Trial Phase
Clinical Trial Sponsors for Eskalith Cr
Sponsor Name